Clinical trial
A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA…
NCT01482715 · pharmaand GmbH, Industry · Completed
Key facts
| NCT number | NCT01482715 |
|---|---|
| Title | A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II) |
| Official title | A Phase I/II, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral Rucaparib in Patients With gBRCA Mutation Ovarian Cancer or Other Solid Tumor |
| Lead sponsor | pharmaand GmbH, Industry |
| Collaborators | Foundation Medicine Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Advanced Solid Tumor With Evidence of Germline or Somatic BRCA |
| Intervention type | Drug |
| Interventions | Rucaparib |
| Enrollment | 136 |
| Start date | Nov 1, 2011 |
| Primary completion | Mar 1, 2019 |
| Completion | May 1, 2019 |
| First posted | Nov 30, 2011 |
| Last update posted | Jun 9, 2023 |
| Countries | Canada, Israel, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: